TICKERNERD
Menu
PGENPGENHealthcare · Biotechnology

PGEN Stock Forecast: Precigen, Inc. Price Predictions for 2026-2027

Last close, 12 Aug 2026
$6.85
−0.15% on the day

The 3 Wall Street analysts covering Precigen, Inc. hold a median 12-month price target of $15 — +111.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 12 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.4B
Ticker Nerd rank
84 / 100
Median analyst target
$15
Analysts covering
3
Total return, dividends reinvested
1W
−0.6%
1M
+28.8%
YTD
+63.9%
1Y
+280.6%
From 52W high
−5.3%
From 52W low
+280.6%
$1.80
$7.23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PGEN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Precigen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Aug 2026
84 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
100
Momentum
95
Value
94
Growth
72
Volatility
71
Quality
49
Accruals
48
Size
34
Issuance
8

Revisions (100): Analysts have, on balance, been raising their forecasts.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26PGENHigh $18Median $15Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $11Median $15High $18

The green dot is the last close — the median target sits +111.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Aug 2026HC Wainwright & Co.MaintainsBuy$14 → $18
3 Aug 2026HC Wainwright & Co.ReiteratesBuy$14
28 May 2026HC Wainwright & Co.MaintainsBuy—
28 May 2026HC Wainwright & Co.MaintainsBuy$11 → $14
14 May 2026CitizensMaintainsMarket Outperform—
14 May 2026HC Wainwright & Co.MaintainsBuy—
26 Mar 2026CitizensMaintainsMarket Outperform—
26 Mar 2026HC Wainwright & Co.MaintainsBuy—
14 Nov 2025HC Wainwright & Co.MaintainsBuy—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
19 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
15 Aug 2025HC Wainwright & Co.MaintainsBuy—
15 Aug 2025JP MorganUpgradeNeutral—
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
12 June 2025JMP SecuritiesReiteratesMarket Outperform—
15 May 2025Cantor FitzgeraldReiteratesOverweight—
20 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform—
20 Mar 2025HC Wainwright & Co.ReiteratesBuy—
23 Jan 2025HC Wainwright & Co.ReiteratesBuy—
22 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PGEN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Precigen, Inc. (PGEN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.0×

Cheaper than 90% of US stocks

Price / sales
28.5×

Cheaper than 8% of US stocks

Price / book
56.1×

Cheaper than 2% of US stocks

EV / EBITDA
−71.2×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
6322.7%

Higher than 99% of US stocks

Earnings growth (YoY)
6322.7%

Higher than 99% of US stocks

Gross margin
94.9%

Higher than 98% of US stocks

Operating margin
41.2%

Higher than 92% of US stocks

Net margin
−184.0%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−837.1%

Higher than 2% of US stocks

Return on assets
−18.1%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PGEN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PGENPrecigen, Inc.$2.4B
84
URGNUroGen Pharma Ltd.$2.4B
82
MLYSMineralys Therapeutics, Inc.$2.4B
24
SLSSELLAS Life Sciences Group, Inc.$2.4B
63
COAGHemab Therapeutics Holdings, Inc.$2.5B
2
TRVITrevi Therapeutics, Inc.$2.5B
53
NKTRNektar Therapeutics$2.5B
54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Precigen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PGEN news & analysis

Precigen: Has To Grow Into Its Valuation

Seeking Alpha · 8 Aug 2026negative

Seeking Alpha reports that Precigen, Inc. surged 266% following FDA approval of PAPZIMEOS, which is now the company's sole revenue driver with $53.1 million in Q2 revenue and low cost of goods sold. The company now trades at a premium valuation near $2.24 billion, while its pipeline faces stiff competition and weaker efficacy than rival treatments.

Why it matters — PGEN watchers would care because the analysis questions whether the company's higher valuation is justified given its reliance on a single approved product and competitive pipeline pressures.

Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 Advancement

Seeking Alpha · 6 Aug 2026positive

Precigen, Inc. was upgraded to a Strong Buy rating, driven by surging PAPZIMEOS revenues and FDA approval for recurrent respiratory papillomatosis. The company achieved profitability in Q2 2026, with PAPZIMEOS revenues doubling quarter-over-quarter to $53.1 million and secured seven years of U.S. market exclusivity, while potential European approval and AdenoVerse platform expansion, including PRGN-2009, could open new opportunities.

Why it matters — PGEN watchers would care because the item highlights a profitability milestone, strong PAPZIMEOS revenue growth, seven years of U.S. market exclusivity, and potential European approval and platform expansion that could unlock significant new market opportunities.

Precigen, Inc. (PGEN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Precigen, Inc. held its Q2 2026 earnings call and released the transcript of the event on Seeking Alpha.

Why it matters — A PGEN watcher would care because the earnings call transcript provides management's discussion of the company's quarterly financial results and operational progress.

Precigen Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

Precigen reported a sharp increase in second-quarter revenue driven by the launch of PAPZIMEOS. The company reached quarterly profitability less than a year after the therapy's August 2025 FDA approval for adults with recurrent respiratory papillomatosis.

Why it matters — For PGEN watchers, the revenue surge and early return to profitability following PAPZIMEOS's approval point to commercial traction for the company's first marketed therapy.

Precigen, Inc. (PGEN) Q2 Earnings and Revenues Surpass Estimates

Zacks Investment Research · 4 Aug 2026positive

Precigen reported Q2 earnings of $0.05 per share, surpassing the Zacks Consensus Estimate of a $0.02 loss and improving from a $0.11 loss per share a year ago.

Why it matters — The earnings beat marks a significant turnaround from both analyst expectations and the prior-year period's loss.

FAQ

Frequently asked questions about PGEN stock

What is the PGEN stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Precigen, Inc. have a median 12-month price target of $15, with estimates ranging from $11 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PGEN stock a buy right now?

Of the 3 analysts covering Precigen, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Precigen, Inc. 84 out of 100 across roughly 4,600 US stocks as at 12 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PGEN?

As at 12 Aug 2026, Precigen, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (100 of 100).

Will PGEN stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +111.7% from the last close, and Ticker Nerd's factor model ranks Precigen, Inc. 84 out of 100 as at 12 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PGEN stock forecast for 2030?

No analyst covering Precigen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $18 over the next 12 months.

How has PGEN stock performed over the past year?

Precigen, Inc. returned +280.6% over the 12 months to 12 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Precigen, Inc. do?

Precigen Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies using precision technology to address diseases in immuno-oncology, autoimmune disorders, and infectious diseases.

What is the latest news on PGEN?

The most recent item we track (Seeking Alpha, 8 Aug 2026): "Precigen: Has To Grow Into Its Valuation". Seeking Alpha reports that Precigen, Inc. surged 266% following FDA approval of PAPZIMEOS, which is now the company's sole revenue driver with $53.1 million in Q2 revenue and low cost of goods sold. The company now trades at a premium valuation near $2.24 billion, while its pipeline faces stiff competition and weaker efficacy than rival treatments.

Company

About Precigen, Inc.

Precigen Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies using precision technology to address diseases in immuno-oncology, autoimmune disorders, and infectious diseases. The company operates through two primary business segments: Biopharmaceuticals and Exemplar. Precigen's therapeutic platforms include the AdenoVerse platform, which leverages a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigens, and UltraCAR-T, which provides chimeric antigen receptor T cell therapies for cancer patients. A significant milestone in the company's development includes FDA approval of PAPZIMEOS (zopapogene imadenovec-drba), the first and only approved therapy for treating adults with recurrent respiratory papillomatosis, a rare and debilitating chronic respiratory disease. Founded in 1998 and headquartered in Germantown, Maryland, Precigen represents an emerging player in the precision medicine sector, combining innovative gene therapy approaches with immunotherapy strategies.

CEO Dr. Helen Sabzevari MPH, Ph.D. · 160 employees · United States · https://precigen.com